The global male infertility diagnosis and treatment market is growing at a CAGR of more than 4% during the forecast period. Infertility in men occurs due to deficiency in sperm formation. Infertility can have several causes and may rely on genetics, fitness, diseases, general health and dietary contaminants. Some crucial causes of male infertility may include abnormal production or functioning of sperms owing to diabetes, HIV, gonorrhea, among others and damage associated with cancer and its treatment. Additionally, problems with the sperm delivery owing to certain genetic diseases, such as cystic fibrosis, damage or injury to the reproductive system and blockage in the testicle are also the major causes for male infertility. 

The major factors contributing to the growth of the global male infertility diagnosis and treatment market include a significant rise in the prevalence of infertility  and considerable advances in the area of infertility. A significant rise in male infertility has been witnessed over the years. This may occur due to the unhealthy lifestyle risk factors, such as psychological stress, alcohol and caffeine consumption, cigarette smoking and obesity and medical history. As per the US Department of Health and Human Services (HHS), out of 100 couples in the US, 12 to 13 have trouble conceiving. Nearly one-third of infertility cases are resulted due to fertility problems in men and another one-third of fertility problems are due to fertility problems in women. 

Major causes of male infertility include erectile dysfunction, varicocele, problems with sperms and blocked tubes. This, in turn, is contributing to the demand for male infertility diagnostic tests and treatment alternatives that supports to understand the cause of infertility, and thereby enables doctors to recommend accurate treatment for the condition. The major diagnostic tests used to diagnose the cause of male infertility include semen analysis, urinalysis and hormonal tests. Hormonal tests evaluate the levels of FSH (follicle-stimulating hormone) and testosterone to determine the overall hormonal system balance and the particular state of sperm production. Prolactin and Serum LH are hormonal tests that may be performed when initial tests indicate the need for these tests. 

Segment Outlook

The global male infertility diagnosis and treatment market is segmented on the basis of diagnostic tests and treatment. Based on diagnostic tests, the market is classified into semen analysis, urinalysis, genetic testing, testicular biopsy, hormonal tests and others. Based on treatment, the market is segmented into drugs, ART therapy and surgery. 

Global Male Infertility Diagnosis and Treatment Market: By Diagnostic Tests

Semen analysis is anticipated to hold the largest share in the market in 2018. Semen analysis is the most suitable and fundamental test with higher sensitivity that supports to detect the condition among men suffering from problem of male infertility. It is a test that evaluates sperm formation and maturity as well as the sperm interaction in the seminal fluid. It can accurately measure the number of sperm, their morphology (size and shape), their motility (ability to move) and the consistency and volume of the ejaculated sample. Normal sperm count ranges from 20 million to 200 million per milliliter. Semen analysis test enables to diagnose low sperm count and therefore, it has a major role to diagnose male infertility.

Global Male Infertility Diagnosis and Treatment Market Share by Diagnostic Tests, 2018 (%)

Regional Outlook

Geographically, the global male infertility diagnosis and treatment market is further segmented into four major regions including North America, Europe, Asia-Pacific, and RoW. A steady increase in the infertility rates among men and the rising demand for assisted reproductive techniques (ART) therapy are contributing to the growth of the market in these regions.

Global Male Infertility Diagnosis and Treatment Market Growth by Region, 2019-2025

Asia-Pacific is estimated to witness lucrative growth in the market during the forecast period

Significant incidences of infertility coupled with initiatives to promote awareness for diagnosis and treatment of the condition is contributing to the growth of the market in the region. For instance, according to the World Health Organization (WHO) estimates, the overall prevalence of primary infertility in India is between 3.9% to 16.8%. In Indian states, the prevalence of infertility ranges from 3.7% in Uttar Pradesh, Himachal Pradesh and Maharashtra, to 5% in Andhra Pradesh, and 15% in Kashmir. Male infertility has found to be the cause of a couple's failure to conceive in a significant number of cases.

Due to this, some initiatives for the treatment of infertility has been witnessed across Asia-Pacific. For instance, ASPIRE, the Asia Pacific Initiative on Reproduction, was founded in 2001 by Bruno Lunenfeld and P C Wong. The initiative is aimed at improving the knowledge and awareness of ART and infertility-related services that can support to improve the quality of patient care. Additionally, this is intended to develop and advance fertility services in the region and raise awareness and understanding for infertility treatment alternatives among healthcare professionals and the public. As a result, such kinds of initiatives are offering significant opportunity to raise awareness about infertility and treatment for the condition. This, in, turn, is estimated to encourage the growth of the market in the region.

Competitive Landscape

Some crucial players in the market include Merck KGaA, Halotech DNA SL, PerkinElmer, Inc., Vitrolife AB and Medical Electronic Systems. In October 2019, Merck Foundation launched a song “Life is Bigger” to raise awareness about male infertility in Africa and Rest of the World. It is a part of community awareness program which is referred to as Merck More than a Mother. This rising awareness initiative is supporting to create awareness among people, and thereby increasing demand for male infertility diagnostic tests and treatment options. 

Mergers and acquisitions and product launches are considered as crucial strategies adopted by these companies to expand market share and gain a competitive advantage over competitors. For instance, in May 2019, Vitrolife AB acquired the business of Parallabs Ltd., its distributor in Ireland and UK for EmbryoScope time-lapse systems. This acquisition will strengthen Vitrolife in Ireland and UK by getting access to a wealth of experience from Parallabs. It will enable to offer customers the complete Vitrolife portfolio from a single sales channel.

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global male infertility diagnosis and treatment market. Based on the availability of data, information related to pipeline products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.